EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
dc.contributor.author | Hoimes, Christopher | |
dc.date.accessioned | 2020-07-01T13:57:35Z | |
dc.date.available | 2020-07-01T13:57:35Z | |
dc.date.updated | 2020-07-01T13:57:34Z | |
dc.identifier.uri | ||
dc.title | EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma | |
dc.type | Conference | |
duke.contributor.orcid | Hoimes, Christopher|0000-0001-8980-2410 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Medicine, Medical Oncology | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Clinical Science Departments |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 2019 ESMO Enfortumab and pembrolizumab in urothelial cancer.pdf
- Size:
- 66.62 KB
- Format:
- Adobe Portable Document Format